News Gist .News

Articles | Politics | Finance | Stocks | Crypto | AI | Technology | Science | Gaming | PC Hardware | Laptops | Smartphones | Archive

Novavax Reports Large Quarterly Revenue Declines, Rethinks Its Strategic Direction

Novavax closed up the day it reported a pivot in direction. The COVID-19 vaccine company, based in Maryland, said during its earnings report that it would move from developing products to instead partnering with larger pharmaceutical companies and licensing its drug technology. Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for the full year 2024, compared to $984 million the previous year.

See Also

ModivCare Full Year 2024 Earnings: EPS Misses Expectations Δ1.77

ModivCare's full year 2024 earnings missed analyst estimates by a significant margin, with the company reporting a net loss of US$201.3m, narrower than the previous year's loss of US$214.9m. Revenue grew 1.3% to US$2.79b, driven primarily by its NEMT segment, but the impact on earnings was substantial due to high cost of sales. The company's shares have declined 17% from a week ago.

Iovance Biotherapeutics Inc (Iova) Q4 2024 Earnings Call Highlights: Strong Revenue and Growth Δ1.76

Iovance Biotherapeutics Inc has announced a strong revenue performance in its Q4 2024 earnings call, driven by the success of its AntagB therapy. The company's robust manufacturing network and favorable medical coverage policies have contributed to this growth. Iovance Biotherapeutics Inc is now expanding its capacity further to meet increasing demand.

Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings Δ1.76

Viatris (VTRS) reported fourth-quarter earnings for December 2024, revealing a revenue decline of 8.1% year-over-year to $3.53 billion, falling short of analysts' expectations. The earnings per share (EPS) also decreased to $0.54, missing the consensus estimate by 5.26%. Key metrics indicate significant challenges for the company, particularly in its emerging markets and generics, which have prompted investor scrutiny regarding future performance.

ChromaDex Corp (CDXC) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advances Δ1.75

ChromaDex Corp reported a remarkable 37% revenue increase in Q4 2024, achieving $29.1 million, alongside a significant net income turnaround of $7.2 million. The company ended the year with strong cash reserves of $44.7 million and no debt, although it faces ongoing supply chain challenges and competitive pressures. E-commerce sales and the NIAGEN ingredient business saw substantial growth, indicating positive market reception despite regulatory and competitive hurdles.

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations Δ1.74

4D Molecular Therapeutics' full year 2024 earnings failed to meet expectations, with a significant widening of its net loss and a decline in its stock price. The company's revenue growth forecast for the next three years is higher than that of the Biotechs industry as a whole, but this may not be enough to offset its current struggles. The company's performance highlights the challenges faced by many biotech companies in achieving profitability.

Corbion Beats Expectations Despite Revenue Decline Δ1.74

Corbion, a Netherlands-based chemicals company, reported full-year 2024 earnings that beat analyst estimates, despite a decline in revenue of 11% compared to the previous year. The company's net income decreased by 37%, but its profit margin remained relatively stable at 3.6%. Looking ahead, Corbion forecasts growth of 5.1% per annum for the next three years.

MODerna Stock Zooms Nearly 16% Higher on Hump Day Δ1.74

Moderna's stock price surged nearly 16% higher following a court ruling in Germany that found Pfizer and BioNTech had violated a COVID-19 patent held by Moderna. The company, best known for producing the Spikevax vaccine, will receive compensation from its rivals for the use of the patent in developing their own COVID jab, Comirnaty. This decision establishes a significant precedent for intellectual property protection in the pharmaceutical industry.

Nvidia (NVDA) Stock Soars on Oversold Conditions Δ1.74

Nvidia's stock advanced on Friday as buyers rushed in to purchase oversold stocks, driven by the company's stronger-than-expected fourth-quarter results and above-average 2025 sales guidance. The chip maker reported a surge in Q4 sales, with revenue from data centers more than doubling year-over-year, and surpassed its sales guidance by almost $2 billion. Despite some challenges in transitioning to new technology, Nvidia's shares have rallied on optimistic views from analysts.

Vinci Partners Investments Posts Strong Q4 2024 Results Despite Earnings Miss Δ1.74

Vinci Partners Investments (NASDAQ:VINP) reported a revenue increase of 32% year-over-year, beating analyst estimates by 16%. However, the company's earnings per share (EPS) missed expectations by 45%, indicating that the growth in revenue was not fully translated into profits. The decline in profit margin to 20% from 49% in the previous year was largely driven by higher expenses.

Nvidia Struggles to Meet Investor Expectations Δ1.73

Nvidia's fourth-quarter report delivered strong revenue growth, exceeding Wall Street estimates with $39.3 billion in sales, but its forecast for gross margin fell short, raising concerns about pricing pressure and competition. The company's stock price plummeted 8.5% on Thursday after the announcement, a decline that has left investors questioning whether the market is still optimistic about Nvidia's prospects. Despite beating expectations, the chipmaker's performance was unable to satisfy investors, leaving its market capitalization below $3 trillion.

Investors Reclaim Control of Pfizer Inc. (Pfe) Amid Vaccine Boom Δ1.73

Pfizer Inc. (NYSE:PFE), the pharmaceutical giant behind a leading COVID-19 vaccine, has seen its stock value rise due to strong demand for its life-saving medication and high expectations from investors. The recent surge in vaccine-related stocks has led to increased investor confidence in Pfizer's ability to deliver on its promises. With the company's vaccine sales reaching new heights, Pfizer is poised to become one of the best-performing biotech stocks.

Marchex Full Year 2024 Earnings: EPS Misses Expectations Δ1.73

Marchex reported a revenue of $48.1 million for the full year 2024, reflecting a 3.6% decline from the previous year, while net losses narrowed to $4.95 million. Despite these figures being largely in line with analyst estimates, the company's earnings per share missed expectations by 10%. Looking ahead, Marchex anticipates a modest revenue growth of 1.3% per annum over the next two years, lagging behind the broader media industry's forecasted growth of 2.7%.

Fubotv Projects Subscriber Fall in Q1 After Q4 Topline Growth, Stock Tumbles Δ1.73

FuboTV Inc (NYSE:FUBO) reported earnings for the fourth quarter of 2024, with revenue growing 8.1% year over year to $443.277 million, marginally missing analyst expectations. Adjusted EPS loss of 2 cents beat analyst estimates, while the company's adjusted EBITDA margin loss stood at (2.0)% versus (12.2)% Y/Y. The company's paid subscribers grew 6.2% Y/Y to 1.64 million in North America.

Aimflex Berhad Full Year 2024 Earnings: EPS: RM0.006 (vs RM0.006 in FY 2023) Δ1.73

Aimflex Berhad's full year 2024 earnings report reveals a slight contraction in revenue and net income, with profit margins remaining relatively stable at 10%. The company's shares have taken a hit, falling 4% from the previous week, amidst concerns over its business performance. These results may be attributed to various factors, including market conditions, operational challenges, or strategic decisions.

Heron Therapeutics' Earnings Send Analysts Scrambling Δ1.73

Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest annual results with strong numbers, including 2.4% better-than-expected revenues of US$144m and substantially lower statutory losses of US$0.09 per share. The company's recent performance has led analysts to update their earnings model, forecasting a 9.6% annualized growth to the end of 2025. However, this growth outlook is still slower than the wider industry, with some analysts valuing Heron Therapeutics at as low as US$4.00 per share.

TECH STOCS RECEDE: Buying Plays Amid Nasdaq Correction Δ1.73

Nvidia's earnings report was a mixed bag, with estimates beat but broader fears about AI and consumer demand prevailing. The resulting sell-off has dropped the Nasdaq to its lowest level since before the election, sparking concerns of a correction. A downturn in tech stocks like Nvidia presents an opportunity to buy proven winners at a discount.

Nvidia Regains $3 Trillion Market Cap Amid Investor Confidence Δ1.73

Nvidia shares rebounded 3.9% on Friday, pushing the tech giant back into the $3 trillion market cap club with Apple, despite a recent slump that wiped out about $273 billion in value and brought the company's market cap to $2.94 trillion. The company reported strong quarterly earnings, with revenue jumping 78% from a year earlier to $39.33 billion, driven by its data center business which saw revenue soar 93% on an annual basis. Nvidia CEO Jensen Huang signaled confidence in the company's future growth, citing strong demand for its chips and a strong quarter ahead.

Nvidia (NVDA) Stock Is Slipping Today Δ1.73

Nvidia's 1% pullback today follows Morningstar's assertion that the stock is "fairly valued," with two technical analysts cautioning about its shares in statements to Yahoo Finance. The research firm expects the company's revenue growth to slow to 21% during its next fiscal year, citing a potential slowdown in demand for AI chips starting in 2026. This assessment contrasts with Morningstar's fair value estimate of $130.

Ionq, Inc. Forecasts us$85.4m Revenue Growth in 2025 Δ1.72

IonQ, Inc. (NYSE:IONQ) has updated its statutory forecasts following its latest yearly results, with analysts now expecting revenues of US$85.4m in 2025, representing a 98% improvement from the last 12 months. This significant acceleration in growth is expected to result in a substantial narrowing of loss per share, projecting a reduction of 25% to US$1.15. The updated forecast underscores the company's projected outperformance against its industry peers.

Methanex Full Year 2024 Earnings: Misses Expectations Δ1.72

Methanex reported its full year 2024 financial results, revealing flat revenue of $3.72 billion and a 5.8% decline in net income to $164 million, falling short of analyst expectations. The company's earnings per share also missed forecasts by 17%, reflecting a profit margin decrease from 4.7% to 4.4%. Despite these setbacks, Methanex anticipates a 10% annual revenue growth over the next three years, outpacing the broader Canadian chemicals industry.

The Future of Biotech Growth Hinges on Estimation Revisions Δ1.72

Recursion Pharmaceuticals (RXRX) delivered a quarterly loss of $0.53 per share, missing revenue estimates by 84.18%, and surpassing consensus EPS estimates just once over the last four quarters. The company's recent earnings surprise reflects the challenges in predicting biotechnology growth, where empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Recursion Pharmaceuticals' current sustainability largely depends on management's commentary on the earnings call.

Nvidia Breaks Records: Doubled Revenues in 2024 Behind Blackwell Δ1.72

During 2024, the company reported revenues of $130.5 billion, increasing 114% from the previous fiscal year. Higher demand for AI capabilities and specifically the Blackwell GPU supported the results. A key factor in the results was the Data Center segment, which reported a record-breaking $35.6 billion in revenue for the fourth quarter.

Nvidia Stock Sell-Off May Fuel Up to 15,375 Surge Wall Street Experts Say Δ1.72

In the latest moves by prominent hedge fund managers, several sold Nvidia stock and bought the iShares Bitcoin Trust exchange-traded fund in the fourth quarter, indicating potential portfolio diversification strategies. Nvidia's strong financial results, including a 78% revenue increase and 71% non-GAAP net income growth, have been overshadowed by its stock price decline due to concerns over pricing power and supply chain issues. Despite this, analysts remain optimistic about the company's prospects.

Investors Flock to BSX as Medical Device Company Hits New Highs Δ1.72

Boston Scientific has nearly doubled the S&P 500's performance over the past five years, driven by its solid quarterly results and beaten expectations. The company's momentum is backed by a decade of organic revenue growth averaging 14.4% year-on-year, indicating its ability to expand quickly without relying on expensive acquisitions. Boston Scientific's expanding margins also provide optionality for long-term growth.

Cronos Group Full Year 2024 Earnings: Revenue Beats Expectations, Eps Lags Δ1.72

Cronos Group's full year 2024 earnings report shows revenue growth of 35% compared to the previous year, with a net income of US$41.1m, but missing analyst estimates by 2.0%. The company's profit margin has increased to 35%, and earnings per share (EPS) have declined to US$0.11, down from a loss of US$0.18 in the previous year. Revenue growth is forecasted to be 11% p.a. over the next three years.